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Abstract  
There is recognition that cognitive problems can contribute to renewed drug taking in former addicts. 
Our previous work has indicated that current smokers show reduced performance on a probabilistic 
reversal learning (PRL) task, relative to former smokers (Butler et al, 2011).  To further explore PRL 
performance and its relevance to smoking, in addition to the role of nicotine, we developed a model of 
nicotine withdrawal-induced deficits in rodents.  A second goal was to test varenicline, an 42 partial 
agonist, for its ability to restore any cognitive impairment.  Acute effects of nicotine and varenicline on 
PRL performance in non-dependent animals were minimal and confined to speed of responding. When 
rats were made dependent on nicotine via osmotic minipumps implanted for 7 days (3.16mg/kg/day), 
repeated tests at specified withdrawal time points revealed PRL disruption peaking at 12 and 24 hours 
following surgical removal of minipumps.  Withdrawal was characterised by significant deficits in the 
number of reversals (p<0.05) speed of responding (p<0.01) and increases in omissions (p<0.05).  
Nicotine (0.2 mg/kg SC) or varenicline (0.3 & 1.0 mg/kg SC) administered 10-min prior to PRL test 
sessions during withdrawal, relieved the performance deficits.  At 24 hrs withdrawal, nicotine and 
varenicline (1 mg/kg) prevented decrements in reversals, in addition to ameliorating slower speed of 
responding.  The high dose of varenicline only, reduced omissions. These results confirm the role of 
nicotine in withdrawal-induced disruption of PRL performance and suggest that the model may be 
useful for investigating efficacy of potential new treatments for smoking cessation. 
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Introduction  
Smoking cessation is typically accompanied by a variety of withdrawal symptoms including mood 
changes (West & Russell, 1988) emotional reactivity (Postma et al, 2001; West & Russell, 1988) and 
craving (Hughes et al, 1991).  There is also now a recognition that cognitive deficits can play a role, 
perhaps acting as drivers of relapse or by reducing resistance to factors that trigger relapse, in former 
smokers.  In some studies, deficits have been found to be predictors of relapse (e.g., Powell et al, 2010) 
whilst in others, superior cognitive performance has been associated with successful abstinence (e.g., 
Nestor et al, 2011).   Amelioration of cognitive problems experienced while attempting to stop smoking 
may therefore constitute a valid target for improving cessation rates, which stand at less than 50% a 
year after treatment with even the most successful of currently available therapies (Kralikova et al, 
2013). 
 
In order to target cognition as a therapy, it is necessary to understand the specific problems that occur 
during withdrawal and the underlying (perturbations of) brain mechanisms. Cognitive problems in 
smokers that are now well documented include disturbances in attention (e.g., Foulds et al, 1996) 
working memory (e.g., Mendrek et al, 2006) and inhibitory control (e.g., Dawkins et al, 2009). Another 
aspect of executive control that appears to be important is performance monitoring.  Performance 
monitoring refers to the ability to monitor feedback in order to guide behaviour. Two studies suggest 
that this type of cognition is relevant to successful abstinence.   Firstly, Nestor and colleagues (2011) 
found that ex-smokers showed greater prefrontal neural activity during error monitoring, compared 
with current smokers. Secondly, Butler et al (2011) used a probabilistic reversal learning task and found 
evidence for better performance monitoring in former smokers compared with current smokers. The 
task used was based on Budhani et al (2006) where participants were required to indicate which stimuli 
of several pairs was correct.  Selection of correct and incorrect stimuli were given positive or negative 
feedback respectively, in the form of points won or lost.  Correct and incorrect stimuli were sometimes 
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reversed and variation of contingencies resulted in false feedback for some responses.  In this study, 
performance monitoring deficits were detected as a greater reaction to false feedback during reversals. 
In addition, slowing that normally occurs in response to the commission of an error was also impaired 
in smokers (Butler, 2013) consistent with a reduced ability to efficiently monitor feedback during 
ongoing performance of the task.  
 
Although these studies imply that good performance monitoring is helpful for successful abstinence 
from tobacco smoking, it is not possible to know if the results arose because of fundamental individual 
differences between current and ex-smokers, or because prolonged nicotine intake alters brain 
mechanisms underlying performance monitoring.   Homomeric α7 nicotinic receptors, thought to be 
particularly dense in the cortex (Gotti et al, 2009) have been detected in both rodent (Murakami et al, 
2013) and human cingulate cortices (Wong et al, 2014) and α4β2 receptors have also been detected in 
the cingulate (Picard et al, 2013).  Cortical sites are thought to mediate some of the cognitive effects of 
nicotine (Stolerman, 1996; Hahn et al 2002) and the cingulate is an area of particular interest in terms 
of performance monitoring (Iannaccone et al 2015; Garavan et al 2003); it is therefore feasible that 
chronic intake of nicotine, as a result of smoking, alters the normal functioning of the cingulate cortex. 
 
In order to investigate if deficits could be related to prolonged self-dosing with nicotine (as opposed to 
other substances in tobacco or pre-existing differences in cognition) we turned to animal studies, as 
there are clear ethical problems associated with prolonged drug dosing in human volunteers.  We used 
the probabilistic reversal learning task (PRL) developed for rodents as, like the human task we used 
previously, it measures reaction to positive and negative feedback; in addition, reward contingencies 
can be varied and reversed (Cools et al 2007;  Hornak et al 2004). Drugs modulating 5-HT function have 
been shown to have analogous effects in both the rat task (Bari et al, 2010) and in human studies 
(Chamberlain et al, 2006).   
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Investigations of cholinergic mechanisms in rodent reversal learning are few and have been restricted 
to “non-probabilistic” tasks (e.g., Roberts et al, 1992; Chen et al, 2004). Therefore, to gain further 
information about the action of nicotine on performance monitoring and its relevance to smoking, we 
first studied a range of acutely administered doses of nicotine, in addition to the acute effects of the 
42 nicotinic-receptor partial agonist varenicline, in animals trained to perform the PRL task.  
Varenicline was used as a tool to gain insight to possible underlying receptor mechanisms as well as to 
evaluate a clinically effective smoking cessation treatment in the task.  Secondly, we used an 
established method for inducing dependence on nicotine in rats (Malin et al 1988; Shoaib & Bizarro 
2005) to examine the consequences of spontaneous withdrawal on performance of the PRL task.  In 
our final experiment, we investigated whether or not acute nicotine and varenicline would ameliorate 
withdrawal-induced deficits. To our knowledge, this is the first study to examine the effects of nicotinic 
ligands in the PRL task; we report here our findings in full, some of which have previously been 
published in abstract form (Silk & Shoaib 2014). 
 
Materials and Methods  
Subjects 
Male hooded Lister rats (Harlan UK) were housed in groups of 4 per cage (RB3, North Kent Cages).  They 
were maintained on a 12 h light-dark cycle with lights off at 1900 h. Ambient temperature was 
maintained between 20 – 22 °C.  Rats were allowed to acclimatise to conditions for minimum 7 days 
before they were placed on a food restriction schedule for 5 days prior to training.  Ad libitum access 
to water in the home cage in addition to access to 15g of chow per rat, ensured that they maintained 
90% of their free-feeding weight.  All procedures complied with local and national ethical requirements 
in accordance with the UK Animals (Scientific Procedures) Act, 1986, in addition to the EU Directive 
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2010/63/EU on the protection of Animals for Scientific Purposes, under a project license issued by the 
UK Home Office. 
Apparatus 
Experimental apparatus consisted of 8 standard operant conditioning boxes (MED-Associates, Georgia, 
VT, USA) housed in fan-ventilated, light- and sound-attenuating chambers.  Each box was fitted with a 
house light, a food hopper on the right-hand wall (standard 45 mg dustless pellets; TestDiet Inc., 
Richmond, Indiana) plus two apertures with LED lights that permitted detection of nose-poke entries 
on the left-hand wall.  Scheduling of contingencies and recording of data were controlled by personal 
computer using MED-PC software (MED-Associates, Georgia, VT, US). 
Drugs 
Nicotine hydrogen tartrate (Sigma-Aldrich, UK) was dissolved in 0.9% saline and the pH was adjusted 
to 7 with NaOH solution. Varenicline tartrate (Tocris, UK) was dissolved in 0.9% saline. For the osmotic 
minipumps, nicotine solutions were dissolved in 0.9% saline and did not require any pH adjustment.  
All doses of drugs are expressed as those of the base. 
Training 
The training procedure used for the PRL was adapted from that used by Bari et al, (2010).  Initially, rats 
were shaped to collect food pellets from the hopper every 30 seconds under a VI-30 schedule.  When 
rats reliably collected the pellets during 60-minute daily sessions, the task was changed to reinforce 
each nose-poke response with a single food pellet. The rats were presented with one hole illuminated 
per trial, assigned randomly to a hole, left or right.  A nose-poke in the correct (illuminated) hole 
resulted in delivery of a single food pellet to the hopper on the opposite wall.  Each new nose-poke trial 
began when the food pellet earned on the previous trial had been retrieved. Approximately 20 
magazine training sessions were required to reach stable performance. 
After stable levels of accuracy were reached, rats were presented with two nose-poke holes, 
simultaneously illuminated.  One of these was the correct location for 80% of the trials, a nose-poke 
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resulting in delivery of a food pellet, and the other was incorrect, resulting in reinforcement for 20% of 
trials.  Holes were illuminated for 30 seconds and if there was no response within this time, the trial 
was deemed an omission which triggered a 5-second time-out.  There was no consequence to a nose 
poke during time-out. A nose-poke in the correct hole on eight consecutive occasions resulted in the 
status of the holes being reversed – the correct hole became incorrect and vice versa.  These sessions 
and subsequent post-training test sessions ended after 199 trials had been completed, or after 40 
minutes, whichever occurred first.   The house light remained on during both training and test stages.   
Experiment 1: Acute nicotine and varenicline. 
Eight subjects trained on the PRL task met the stability criteria and were tested with nicotine and 
varenicline acutely. Using a repeated measures design, rats were administered each dose of nicotine 
or varenicline in a randomised order, with one day of normal training between to allow between-
session washout. Doses of either nicotine or varenicline were injected SC ten-minutes before each 
session; rats remained in the home cage during this pre-session period.  This pretreatment time is based 
on previous pharmacokinetic data derived from nicotine discrimination experiments and plasma 
nicotine determinations indicating near peak levels of absorption and penetration into the brain 10 min 
after injection (Pratt et al 1983). 
Doses of nicotine were: vehicle, 0.025, 0.05, 0.1, 0.2 and 0.4 mg/kg.  Doses of varenicline were: vehicle, 
0.03, 0.1, 0.3 and 1 mg/kg.   
 
Experiment 2: Withdrawal from chronic nicotine treatment 
Subjects were 16 rats weighing 280-300g at the start of the experiment and pre-trained on the PRL 
task.  Following training, rats underwent surgery to implant Alzet osmotic minipumps (2ML2) for 
chronic nicotine administration. Thirty to sixty minutes before implantation, minipumps were primed 
to deliver 3.16 mg/kg/day nicotine or saline solution and incubated in physiological saline. Rats were 
then anaesthetised using isoflurane and an incision made at the top left of the back. The minipump was 
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inserted subcutaneously and the incision closed using surgical clips and pain relief was administered 
systemically (carprofen 5mg/kg IP).  Following surgery, rats were placed in an incubator while 
recovering; meloxicam for pain relief and enrofloxacin (antibiotic) were administered post-surgery 
where necessary.  Minipumps remained implanted for 7 days, when they were removed under 
isoflurane anaesthesia. Topical analgesia was applied using lidocaine and bupivacaine following the 
removal of the osmotic minipumps. Rats subsequently underwent PRL test sessions at 6, 12, 24, 48, 72 
and 96 hours from the time the osmotic pumps were removed.  Following PRL test session conducted 
at 12 hours post withdrawal, all rats received further pain relief administered systemically (carprofen 
5mg/kg IP). We have previously shown that nicotine delivered via these osmotic minipumps in this dose 
(3.16mg/kg/day) for 7 days induces a robust level of physical withdrawal from nicotine as measured on 
somatic signs (Wing & Shoaib 2007) and also on attentional processes in the 5-choice serial reaction 
time task (Bizarro & Shoaib 2005).   
 
Experiment 3: Nicotine and varenicline administered during withdrawal 
Subjects were 32 rats weighing 280—300g at the start, who were trained and implanted with nicotine-
primed osmotic minipumps, as described under Experiment 2.  Minipumps remained implanted for 7 
days and were subsequently removed under isoflurane anaesthesia.  Following pump removal, rats 
were allocated to one of four treatment groups – withdrawal + saline vehicle (control), withdrawal + 
nicotine 0.2 mg/kg (nicotine), withdrawal + varenicline 0.3 mg/kg (varenicline low dose), withdrawal + 
varenicline 1.0 mg/kg (varenicline high dose).  They then completed PRL test sessions at 12 and 24 
hours post-pump removal, following acute subcutaneous injections (t - 10 mins) according to their 
allocated treatment group.   
 
Data Analysis 
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In all experiments data collected were: total number of ‘correct’ and ‘incorrect’ responses, total 
number of omissions (trials where no response was made for 30 seconds), total number of pellets 
earned, number of reversals completed (eight consecutive correct nose-pokes), total session time, 
response latency (mean time, in seconds, between aperture light coming on and a nose-poke).  Two 
ratios were calculated: win-stay ratio (number of trials where the same aperture was selected following 
a rewarded trial/total rewarded trials) and lose-shift ratio (number of trials where the opposite 
aperture was selected following a non-rewarded trial/total non-rewarded trials). 
 
For the first experiment, normally distributed data were analysed by Repeated Measures Analysis of 
Variance (RMANOVA) with treatment group as the repeated factor.  Significant main effects were 
further analysed using paired t-tests to compare performance with controls. Where variables were not 
normally distributed (latencies) data were first analysed by Friedman Test for paired samples and 
individual comparisons were made using a Wilcoxon Test. 
 
For the two withdrawal experiments, there were no differences between groups at baseline (T=0 hrs) 
and with the exception of omissions in the first withdrawal study, data were normally distributed. Data 
were therefore first analysed using RMANOVA with factors of Group and Time (repeated).  As we 
needed to know where changes in performance differed from the baseline point before withdrawal, 
significant interactions arising from RMANOVA were explored using paired t-tests within each group.  
This enabled us to compare performance at each post-pump removal time point to baseline. This 
approach was deemed preferable to using multiple comparisons, such as Bonferroni, which perform all 
possible comparisons regardless of their relevance to the scientific question and in doing so, increase 
the possibility of Type II errors (accepting the null hypothesis, when the alternative is true; Perneger, 
1998).   The use of paired t-tests within each group resulted in five comparisons per group.  Therefore, 
in order to reduce the possibility of Type I errors (rejecting the null hypothesis, when the alternative is 
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true) p-values were adjusted using Benjamini-Hochberg method to control for false positives 
(Benjamini & Hochberg, 1995).  Unless otherwise stated, all p-values refer to adjusted values.  For some 
variables, significant interactions were also investigated using independent t-tests to examine between 
group differences at the 12 hr or the 24 hr time points.  As data for omissions in the first withdrawal 
study were not normally distributed, they were analysed by Friedman Test for paired samples and 
individual comparisons used a Wilcoxon Test.   
Results 
Experiment 1: Acute nicotine and varenicline 
Acute nicotine injections did not affect reversals (F5,35=1.074, p>0.3) omissions (F5,35=1.038, p>0.4) 
errors (F5,35=0.673, p>0.6) number of pellets earned (F5,35=0.330, p>0.8) win-stay (F5,35=0.259, p>0.9) or 
lose-shift ratios (F5,35=1.821, p>0.1); see Table 1.  Response latencies increased at the higher doses of 
nicotine and a Friedman Test indicated a difference between the groups overall (2(5)=11.929, p<0.05); 
individual Wilcoxon comparisons with vehicle were not significant (Z’s<-0.1, p’s>0.05). Likewise there 
was a significant main effect of dose for total session time (F5,35=2.597, p<0.05) but individual 
comparisons were not significant (all t7’s<-3.2, p’s>0.07). Similarly, varenicline did not alter 
performance (Table 1) as measured by reversals (F4,28=0.727, p>0.5) omissions (2(4)=6.667, p>0.1) 
errors (F4,28=0.293, p>0.8) pellets earned (F4,28=0.544, p>0.7) win-stay (F4,28=1.443, p>0.2) or lose-shift 
ratios (F4,28=0.538, p>0.7).  However, both response (F4,28=7.728, p<0.001) and total session times 
(F4,28=6.964, p<0.01) were faster following varenicline treatment. Individual comparisons revealed that 
this was true for all doses of varenicline (latency: all t7’s>3.2, p’s<0.05; total time: all t7’s>3.0, p’s<0.05) 
compared to controls. Therefore, acute injections of nicotine did not significantly alter performance of 
the PRL task, whereas varenicline increased response rates and reduced the time taken to complete 
the task.  
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Experiment 2: Withdrawal from chronic nicotine treatment 
After pump removal, the number of reversals completed changed over time (main effect: F6,84=4.162, 
p<0.01) but there were no overall differences between the groups (F1,14=3.626, NS).  RMANOVA 
revealed a significant time-by-group interaction (F6,84=2.255, p<0.05).  This was due to a decrease in 
performance of the nicotine withdrawal group only; reduced reversals were seen 12 and 24 hrs after 
pump removal, although this was only significant at 12 hrs (t7=4.889, p<0.02; Figure 1A).  Response 
latencies were also disrupted in the nicotine withdrawal group. RMANOVA revealed a significant effect 
of time (F6,84=35.709, p<0.001) but not group (F1,14=3.543, NS) with a significant interaction (F6,84=4.809, 
p<0.001). The interaction was due to considerable slowing of responding in nicotine withdrawn animals 
such that response times were greater than baseline at 6 (t7=-7.194, p<0.001) 12 (t7=-5.757, p<0.01) 24 
(t7=-5.897, p<0.01) and 48 hrs (t7=-2.851, p<0.05) after pump removal.  There was also some disruption 
in the control group, but this was of much smaller magnitude and significant only at the 24 hr time 
point (t7=-5.342, p<0.01; Figure 1B).  Similarly, the total time to complete the PRL task was prolonged 
in the nicotine withdrawal group. RMANOVA revealed significant effects of time (F6,84=32.104,p<0.001) 
and group differences (F1,14=6.238, p<0.05) with the nicotine withdrawn animals taking longer overall.  
Greater disruption in the drug treated group was evidenced by a significant time-by-group interaction 
(F6,84=5.340,p<0.001).  Paired t-tests indicated a small change in the control group at the 24 hr time 
point (t7=-3.694, p<0.05) but a much larger effect in the nicotine treated group at all time points (all 
t7’s>-2.773, p’s<0.05) except 72 hrs (t7=-1.857, NS; Figure 1C). 
 
The results for the remaining variables measured are shown in Table 2.  Whilst there was no change 
across time in the control group (2(5)=8.489, NS) the number of omissions increased in the nicotine 
withdrawal group (2(5)=25.502,p<0.001).  Increased omissions peaked at 24 (Z=-2.371, p<0.05) and 48 
hrs withdrawal (Z=-2.375, p<0.05). RMANOVA of data for the number of pellets collected indicated a 
significant time-by-group interaction (F6,84=3.995, p<0.01) although no main effects of time 
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(F6,84=1.004, NS) or group (F1,14=1.682, NS) were apparent.  The interaction was likely due to increases 
in pellet collection for the control group, but decreases for the nicotine withdrawal group, although 
paired t-tests were not significant (all t7’s<±2.500, p’s>0.05).  An independent groups t-test however, 
at the 24 hr time point, indicated that pellet collection in the withdrawal group was significantly lower 
than the control group (t14=3.010, p<0.01).  Similarly, for errors that animals made, there was a 
significant time-by-group interaction (F6,84=2.369, p<0.05) but no main effect of time (F6,84=1.688, NS) 
or group (F1,14=0.880, NS).  Again, paired t-tests were not significant at any time point in either 
treatment group (all t7’s<±2.800, p’s>0.05) but at 12hrs, an independent t-test indicated significantly 
more errors in the withdrawal group, compared with controls (t14=-2.233,p<0.05).  Win-stay behaviour 
was also disrupted by nicotine withdrawal.  There was a significant main effect of time (F6,84=5.128, 
p<0.05) and group by time interaction (F6,84=2.520, p<0.05) but no overall group difference (F1,14=3.886, 
NS).  Paired t-tests were not significant in either group (all t7’s<±3.300, p’s>0.05) although independent 
t-tests indicated significantly lower performance in the withdrawal group, relative to controls, at 12 
(t14=2.524, p<0.05) and 24 hrs (t14=2.401, p<0.05).  There were no significant changes in either group, 
for lose-shift behaviour (Group: F1,14=0.503, NS; Time: F6,84=0.715, NS; Interaction: F6,84=1.374, NS).  
Thus withdrawal from nicotine disrupted performance by increasing omissions, errors and response 
times.  It also decreased the number of reversals completed, the number of pellets collected and 
reduced win-stay behaviour.   
 
Experiment 3: Nicotine and varenicline administered during withdrawal 
Following removal of the pumps, the number of reversals completed changed over time (main effect: 
F5,140=16.34, p<0.01).  Although there were no overall differences between the groups (F3,28=0.829, NS) 
RMANOVA revealed a significant time-by-group interaction (F15,140=1.765, p<0.05).  In the saline treated 
group the number of reversals completed decreased over time, to reach a low point 24 hrs after pump 
removal (t7=5.134, p<0.01; Fig 2A); thereafter reversals recovered to baseline levels.  In the group 
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treated with nicotine, reversals were not significantly different from baseline at any time point (all 
t7’s<2, p’s>0.2) and the same was true for the group given the larger dose of varenicline (all t7’s<3.6, 
p’s>0.05).  In animals given the smaller dose of varenicline, performance followed a similar pattern to 
controls, in that significant reductions in reversals were seen at 24 hrs (t7=4.333, p<0.05) and also at 30 
hrs (t7=3.543, p<0.05). Thus both nicotine and the larger dose of varenicline only, prevented 
decrements in reversals seen 24 hrs into withdrawal. 
 
RMANOVA of response latencies indicated significant time (F5,140=30.189, p<0.0001) and time-by-group 
interactions (F15,140=2.334, p<0.01) but no overall differences between groups (F3,28=2.112, NS).  
Responding slowed significantly in the group treated with vehicle, at all time points after baseline (all 
t7’s>-2.54, p’s<0.05) with the exception of the final time point, where latencies were similar to baseline 
and not significantly different (t7=-1.655, NS; Fig 2B). 
A similar pattern was seen in the other treatment groups where responding slowed at all time points 
(t7’s>-2.93, p’s<0.05) except the 12hr point, where latencies were not different from baseline (t7’s<0.6, 
p’s>0.5).  However, as withdrawal slowing varied considerably in the controls at 12 and 24 hrs, these 
data were further analysed with between group t-tests.  In Figure 2B it can be seen that at 12 hrs, there 
was significant reversal of withdrawal slowing by nicotine (t14=2.325, p<0.05) and by the larger dose of 
varenicline (t14=2.831, p<0.05) but not by the lower dose (t14=1.212, p>0.2).  Likewise, at 24 hrs 
withdrawal, nicotine (t14=2.760, p<0.05) and varenicline 1 mg/kg (t14=3.032, p<0.01) reversed slowing, 
but not varenicline 0.3 mg/kg (t14=0.429, p>0.6).  Similarly, overall omissions also increased over time 
(F5,140=35.547, p<0.0001) and there was a significant time-by-group interaction (F15,140=2.161, p<0.05 ) 
but no overall group differences (F3,28=1.638, NS).  Figure 2C shows that withdrawal-induced increases 
in omissions were significant in controls at 6, 24 and 30 hrs (t7’s>-4.31, p’s<0.01).  At 24 hrs withdrawal, 
treatments reduced omissions somewhat, but this was only significant for the group treated with the 
largest dose of varenicline (t14=2.505, p<0.05). 
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The results for the remaining variables are shown in Table 3.  The total number of pellets collected 
varied across time points (F5,140=30.929, p<0.0001) and there was a significant time-by-group 
interaction (F15,140=1.917, p<0.05); between groups factor was not significant (F3,28=1.096, NS).  At 24 
and 30 hrs, pellets collected were considerably reduced as withdrawal progressed in the control group 
(respectively: t7=5.468, p<0.01; t7=4.619, p<0.01). At 24 hrs, none of the other treatment groups were 
significantly different from baseline, indicating reversal of the withdrawal effect (t7’s<2.9, p’s>0.05).  
Reductions in pellets collected were still evident at 30 hrs in the group treated with the smallest dose 
of varenicline (t7=5.292, p<0.01) but not with the highest dose (t7=1.990, p>0.1) suggesting that 
varenicline at 1 mg/kg had a prolonged effect on this measure. 
 
Errors were affected overall during withdrawal (time: F5,140=26.355, p<0.0001).  RMANOVA revealed a 
significant time-by-group interaction (F15,140=2.913, p<0.001) but no between group differences 
(F3,28=0.746, NS). At 24 hrs, there was a significant reduction in errors committed in the vehicle control 
group (t7=5.126, p<0.01) and this was also true of the group administered 0.3 mg/kg varenicline 
(t7=6.020, p<0.01). Reductions in the nicotine treated group (t7=1.276, p>0.3) and those given the larger 
dose of varenicline (t7=1.928, p>0.2) were not significantly different from baseline, indicating that these 
two treatments prevented the withdrawal effect on errors. 
 
For total session time, win-stay and lose-shift ratios, RMANOVA revealed significant overall time effects 
(respectively: F5,140=47.717, p<0.001; F5,140=2.793, p<0.02; F5,140=3.094, p<0.02).  However, there were 
no significant interactions (respectively: F15,140=1.697, NS; F15,140=0.758, NS; F15,140=1.002, NS) or 
between group effects (respectively: F3,28=1.904, NS; F3,28=0.483, NS; F3,28=0.895, NS ) so these 
measures were not further analysed.  Both nicotine and varenicline were therefore able to ameliorate 
withdrawal-induced disruption in performance of the PRL task, by preventing decrements in reversals, 
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speed of responding and pellet collection; they also reversed withdrawal-induced changes in errors and 
omissions. 
 
Discussion 
 
We carried out a series of experiments to investigate the effect of nicotine and withdrawal following 
chronic nicotine treatment on PRL responding in rats and also to determine if a clinically effective 
treatment would ameliorate any withdrawal-induced deficits. The acute effects of nicotine and 
varenicline on PRL performance were minimal and confined to speed of responding. In the case of 
nicotine, total time on task tended to increase (albeit non-significantly) at the highest doses. In 
contrast, varenicline increased response rates and reduced total time on task at all doses tested.  
Withdrawal from chronic nicotine treatment disrupted performance of PRL as seen by a reduced 
number of reversals, prolonged response latencies and time on task, accompanied by increased 
omissions.  Disruption peaked at 12 – 24 hrs after pump removal, with a small increase in errors and 
with win-stay behaviour also being reduced somewhat.  A reduction in pellet collection was seen at 24 
hrs withdrawal.  After 96 hrs, PRL performance was largely returned to baseline levels. 
 
The time course of the withdrawal effect is interesting in comparison with human studies of 
performance monitoring.  Nestor and colleagues (2011) found differences in neural activity during error 
monitoring between former and current smokers.  In their study, volunteers smoked as usual before 
beginning the experimental procedure, but it was not possible to exclude the probability that 
volunteers entered early withdrawal during the experimental procedure. In the PRL study by Butler et 
al (2011) again differences were found between former and current smokers. In this study however, 
volunteers either smoked just prior to testing or had been abstinent from 11pm the night before and 
the largest difference from former smokers that was seen, was in those who smoked prior to testing.  
The current study clearly shows withdrawal-induced disruption peaking around 24 hrs, but results of 
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human studies however, are ambiguous, as neither have studied the effect of withdrawal in a 
controlled manner, over the same time course, or over an extended period of abstinence. Human 
studies now need to establish the time course of any withdrawal-induced disruptions and if there is 
any recovery within a time period similar to that observed here. Long-term abstinence-induced deficits 
in cognition are important modulators of cessation success but given that most people who attempt to 
stop smoking will relapse during the very early stages of withdrawal (Hughes et al, 2004) early 
treatment could have considerable impact on cessation rates (Powell et al, 2010). 
 
In the final study, disruption of PRL performance by withdrawal from chronic nicotine treatment was 
replicated, with the exception that significant alterations in total session time and win-stay ratios were 
not seen. Both nicotine and the largest dose of varenicline prevented withdrawal-induced decrements 
in reversals, slowing of responding, increased omissions and changes in the number of errors.  
Reduction of pellet collection was ameliorated by all three treatments (nicotine and both doses of 
varenicline) with the highest dose of varenicline having the most prolonged effect.  Both nicotine and 
varenicline therefore were able to restore PRL performance after withdrawal-induced disruption; the 
results generally validate the model as suitable for further studies investigating potential treatments 
for smoking cessation. 
 
 
Clear withdrawal-induced disruptions were seen in the number of reversals that animals made, 
suggesting deficits in cognitive flexibility associated with abstinence. This contrasts with results 
obtained by Nesic et al (2011) who found impaired set-shifting in satiated smokers, compared with 
abstinent smokers, using the Intra-Extra Dimensional Set-Shift (IED) test.  There are two possibilities to 
explain this apparent discrepancy.  Firstly, effects of smoking/withdrawal on cognitive flexibility may 
depend on degree of dependence. Negative correlational relationships between smoking dependence 
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and cognitive flexibility have been reported (Martin et al 2000, Kalmijn et al 2002) and in the Nesic et 
al study (2011), impaired set shifting following smoking was seen only in volunteers with a high degree 
of dependence, not those with less dependence. Secondly, whether or not a reward-based task is used 
may be factor.  As in the current task, animal models of cognitive flexibility necessarily use food reward 
to train animals to perform (e.g., Allison & Shoaib 2013).  Tests used in human studies are not always 
reward based – for example, the Wisconsin Card Sorting Test and the IED test used by Nesic et al (2011) 
involved using feedback in the form of “correct” or “wrong”, rather than rewards such as points or 
money. Indeed there is some evidence that in certain populations, problems of cognitive flexibility are 
only manifest as reward-based inflexibility (Boog et al, 2014). Further studies in human smokers using 
reward-based tasks might therefore be informative. Both nicotine and varenicline reversed the 
withdrawal induced deficit in reversals in this study; it would therefore be of interest also, to determine 
the effects of varenicline on cognitive flexibility in human smokers. 
 
Speed of responding in the PRL was also disrupted during withdrawal from chronic nicotine treatment. 
This deficit was also ameliorated by both nicotine and varenicline. Interestingly, restoration of response 
speed was unlikely due to direct psychomotor stimulant effects of either nicotine or varenicline.  
Nicotine did not alter response speeds (except possibly to produce slowing at the highest dose) when 
administered to naïve animals. In the case of varenicline, increased response rates in naïve animals 
were seen at all doses tested, but only the largest dose tested was able to restore performance during 
withdrawal. The inefficacy of lower doses in withdrawal suggests that some tolerance developed during 
chronic treatment.  This would be consistent with work in humans indicating that smokers can tolerate 
higher doses of varenicline than non-smokers (Faessel et al, 2006).  It also suggests that the chronic 
dosing regimen used in this model produced at least some adaptation in brain mechanisms appropriate 
to the human situation, where smokers have often been ‘self-dosing’ with nicotine for many years. 
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Win-stay ratios (sensitivity to positive feedback) were reduced in the first withdrawal experiment, but 
in the second study, these ratios showed only a non-significant tendency to be disrupted (at 24 hrs).  
Withdrawal-induced alterations in lose-shift ratios (sensitivity to negative feedback) were also 
anticipated, but not seen.  In recent years, evidence has accumulated for disrupted sensitivity to 
feedback in depressed patients.  Using a variety of tasks, changes in sensitivity to positive- or negative-
feedback, or both, have been reported (Chase et al, 2010).  In some studies, abnormal reaction to 
feedback in patients has been correlated with anhedonia (Steele et al, 2007).  Whilst it is not possible 
to measure affect directly in rodents, changes in win-stay/lose-shift ratios might have occurred due to 
the aversive nature of withdrawal altering sensitivity to feedback.   Indeed, in an earlier study in rats 
on reward responsiveness, Pergadia et al (2014) saw reduced reward-related response bias during 
nicotine withdrawal.  These authors also found a similar reduction in human smokers, although 
approximately half of these volunteers had a history of depression.  Finally, in a study in human smokers 
that excluded history of depression, using the Cambridge Gambling Task, Austin et al (2014) showed 
that in early abstinence from smoking, reactivity following gains was reduced; this would be consistent 
with an expectation that withdrawal should reduce sensitivity to positive feedback.  Unfortunately, 
because of the lack of a statistically significant disruption in our final study, it is not possible to comment 
further on any effect of nicotine or varenicline.  
 
The reasons for the lack of sensitivity of these measures to withdrawal are not completely clear. Firstly 
however, it should be noted that performance on the task was very good, with win-stay ratios of around 
80% (compared to, for example, around 60% in Bari et al, 2010) possibly making it hard to disrupt 
performance.  Alternatively, it may be that longer dosing with nicotine is required to see robust 
disruptions in win-stay or lose-shift ratios. As previously noted, changes in cognition occurring during 
smoking cessation may depend on the degree of dependence (Brooks & Jackson, 2008; Nesic et al, 
2011). 
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We used varenicline, not only to validate the model in terms of current treatments, but also as a tool 
to gain some insight into nicotinic receptor mechanisms.  Interestingly, a “partial” effect that might 
have been anticipated from a partial agonist was not seen; where withdrawal-induced disruption of 
performance was evident, varenicline was clearly as effective as the full agonist nicotine.  Interestingly, 
some drug discrimination studies report full generalisation of the nicotine stimulus (Rollema 2007; 
Jutkiewicz et al 2011; Cunningham 2012) to varenicline, rather than partial generalisation (Smith et al 
2007; LeSage et al 2009; Cunningham & McMahon 2013) as might be expected of a partial agonist. 
Whilst the degree of generalisation seen in drug discrimination studies depends partly on how it is 
measured, partly on the training methods used and the doses of nicotine and varenicline, Jutkiewicz et 
al (2011) have suggested that some nicotine discriminative stimuli can be based on mainly 42 
receptors, but others can based on multiple nicotinic receptor mechanisms.  This is an entirely plausible 
explanation for the varied results with varenicline in the drug discrimination assay.  In a similar vein, 
our results with varenicline may have arisen because the particular chronic dosing regimen with 
nicotine and subsequent withdrawal, affected more than just 42 receptors.  There is evidence that 
varenicline is a partial agonist at 42 nicotinic receptor subtypes (Coe et al, 2005; Rollema et al, 2007) 
but also that is has affinity for and efficacy at others.  Mihalak et al (2006) investigated functional 
activity at rat neuronal nicotinic receptors and reported efficacy values of 13.4% at 42, 93% at 7 
and 75% at 34 subtypes.  Potency values (EC50) were respectively 2.3 μM, 18 μM and 55 μM.  Grady 
et al (2010) also report considerable efficacy of varenicline at 7 and 34 subtypes, although their 
data were derived from mice.  Thus on the basis of potency and efficacy, 7 receptors become a 
possible target for the action of varenicline in our study.  In addition, 7 receptors do not appear to 
undergo lasting inactivation by chronic nicotine exposure and are expressed particularly in the cortex 
(Gotti et al, 2009). We therefore tentatively suggest that ligands with specific action at 7 subtypes 
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might be particularly suitable for ameliorating withdrawal-induced deficits in performance monitoring, 
although clearly further studies would be required to establish this. 
 
The time course of withdrawal-induced disruptions to PRL performance were similar to those 
previously observed using a visuospatial attention task. Removal of osmotic minipumps from nicotine-
dependent subjects elicited peak deficits in number of omission errors and increases in latency to 
respond (Shoaib & Bizarro 2005).  In contrast to the current results however, these withdrawal effects 
may not have involved α7 nicotinic receptors, as the selective antagonist methyllycaconitine did not 
induce attentional deficits, but a non-selective antagonist did (dihydro-β-erythroidine; Shoaib & Bizarro 
2005).  Taken together with the results of our studies using PRL, this would seem to suggest that 
nicotine may be able to exert effects on different cognitive domains via dissociable mechanisms.  Whilst 
preclinical studies have pointed to a role for dopamine in the effects of nicotine on attention (Cole & 
Robbins, 1989; Shoaib & Bizarro, 2005), nothing is known about its action on PRL performance.  It is 
therefore important to investigate this further, not only from the point of view of developing new 
treatments to help smoking cessation, but also because of the growing evidence for differential 
involvement of nicotinic receptor subtypes in healthy and disordered human cognition (e.g., Martin-
Ruiz et al 1999; Reinvang et al 2010; Evans et al, 2013). 
 
Finally, whilst the use of osmotic minipumps for nicotine administration may not mimic absolutely the 
peaks and troughs of nicotine self-dosing in human smokers, it provides a simple means of dosing rats 
with nicotine for periods of 1 to 4 weeks in order to produce “physiological” (or somatic) dependence, 
demonstrated either by spontaneous withdrawal or precipitated withdrawal.  It is the nature of the 
slow, prolonged nicotine exposure, that allows adaptations to develop, and which do not develop as 
easily with repeated systemic injections of nicotine (Corrigall, et al 1989). In addition, the constant 
infusion of nicotine via minipumps achieves plasma levels comparable to those found in smokers 
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(Henningfield, London, & Benowitz, 1990; Jansson, Andersson, Fuxe, Bjelke, & Eneroth, 1989).  It 
therefore provides a relatively straightforward model that can be used in conjunction with cognitive 
tasks that are translatable to the human situation. 
 
In conclusion, we have developed an animal model of nicotine withdrawal-induced deficits in 
probabilistic reversal learning, an aspect of executive control that appears to be impaired in human 
smokers. Performance deficits peaked around 24 hours into withdrawal and were largely recovered by 
96 hours. Both nicotine and varenicline were able to restore withdrawal-induced deficits.  Our results 
suggest that the model may be useful for investigating the efficacy of putative new treatments for 
smoking cessation. 
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Table 1.  The effect of nicotine and varenicline on probabilistic response reversal (PRL) in rats. 
 
 nicotine (mg/kg) 
 0 0.025 0.05 0.1 0.2 0.4 
Reversals (n) 4.44 ± 0.3 4.5 ± 0.7 4.38 ± 0.8 5.25 ± 0.6 4.38 ± 0.5 5.38 ± 0.6 
♯ Response latency (s)  3.46 ± 0.2 2.93 ± 0.7 3.38 ± 0.9 3.01 ± 1.4 3.71 ± 1.8 3.67 ± 2.2 
Omissions (n) 0.82 ± 0.3 0.38 ± 0.3 0.0 ± 0.0 1.13 ± 1 1.75 ± 1.8 2.75 ± 1.6 
Pellets (n) 117.8 ± 1.0 119.2 ± 2.9 120.0 ± 3.1 121.0 ± 2.8 120.8 ± 2.2 121.6 ± 3.2 
Errors (n) 71.4 ± 2.3 66.1 ± 2 68.6 ± 3 66.2 ± 4.3 68.6 ± 1.8 68.1 ± 3.1 
Session Time (s) 1249.8 ± 60.9 1178.3 ± 76.4 1252.3 ± 91.1 1378.5 ± 125.6 1440.5 ± 147.9 1552.7 ± 124.3 
Win-Stay Ratio 0.810 ± 0.02 0.825 ± 0.03 0.813 ± 0.04 0.813 ± 0.04 0.825 ± 0.02 0.804 ± 0.02 
Lose-Shift Ratio 0.573 ± 0.06 0.610 ± 0.05 0.619 ± 0.06 0.586 ± 0.04 0.560 ± 0.06 0.496 ± 0.05 
 varenicline (mg/kg) 
 0 0.03 0.1 0.3 1  
Reversals (n) 5.5 ± 0.8 5.13 ± 1.1 6.38 ± 0.9 6.88 ± 0.8 6.25 ± 0.9  
Response latency (s) 3.02 ± 0.2 2.43 ± 0.2* 2.35 ± 0.2* 2.25 ± 0.2* 2.29 ± 0.2*  
♯ Omissions (n) 0.0 ± 1.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0  
Pellets (n) 120.2 ± 3.5 120.2 ± 4.6 124.8 ± 2.2 125.0 ± 3.9 123.7 ± 2.3  
Errors (n) 61.0 ± 3.1 64.8 ± 5 63.2 ± 2.3 62.1 ± 3.8 61.7 ± 2.3  
Session Time (s) 1100.6 ± 30.9 970.5 ± 36.4* 964.9 ± 27.2* 938.8 ± 43.3* 937.3 ± 32.4*  
Win-Stay Ratio 0.888 ± 0.02 0.846 ± 0.03 0.866 ± 0.02 0.888 ± 0.02 0.867 ± 0.03  
Lose-Shift Ratio 0.627 ± 0.05 0.566 ± 0.03 0.598 ± 0.06 0.602 ± 0.05 0.610 ± 0.06  
 
Data are means (± s.e.m.) for n= 8 rats, except where data were not normally distributed, ♯ so are medians 
(± semi-quartile range).  
*p<0.05 w.r.t. corresponding vehicle controls. 
 
Table 2.  The effect of withdrawal from chronic nicotine treatment, across time, on probabilistic 
response reversal performance. 
 
 Omissions (n) 
 T=0 hrs T=6 hrs T=12 hrs T=24 hrs T=48 hrs T=72 hrs T=96 hrs 
vehicle 1 ± 0.25 1 ± 1 1.5 ± 1.75 3 ± 5.75 1.5 ± 3.25 1.5 ± 2 0 ± 0.5 
nicotine 0 ± 1 4.5 ± 3.5 2 ± 2.75 10.5 ± 10.5 * 3 ± 2.5 * 1.5 ± 3 1 ± 2.5 
 Total Pellets (n) 
 T=0 hrs T=6 hrs T=12 hrs T=24 hrs T=48 hrs T=72 hrs T=96 hrs 
vehicle 116.7 ± 3.1 118.8 ± 2.71 120.3 ± 3.5 124.1 ± 2.38 122.7 ± 2.23 121.3 ± 2.07 116.1 ± 2.44 
nicotine 123.1 ± 2.2 120.2 ± 3.7 114.7 ± 2.56 105.2 ± 5.81  118.1 ± 2.87 119.7 ± 3.42 120.2 ± 2.68 
    Errors (n)    
 T=0 hrs T=6 hrs T=12 hrs T=24 hrs T=48 hrs T=72 hrs T=96 hrs 
vehicle 64.2 ± 2.79 66.8 ± 3.46 65.1 ± 2.84 63.5 ± 2 62 ± 3.55 66.2 ± 2.33 70.7 ± 3.31 
nicotine 64.1 ± 2.75 72.8 ± 3.68 74.5 ± 3.1  63.3 ± 4.88 69.8 ± 4.7 70.3 ± 2.47 62.3 ± 2.81 
 Win Stay Ratio 
 T=0 hrs T=6 hrs T=12 hrs T=24 hrs T=48 hrs T=72 hrs T=96 hrs 
vehicle 0.855 ± 0.013 0.809 ± 0.025 0.855 ± 0.016 0.855 ± 0.024 0.865 ± 0.022 0.866 ± 0.018 0.834 ± 0.017 
nicotine 0.851 ± 0.012 0.739 ± 0.037 0.772 ± 0.029    0.773 ± 0.031  0.823 ± 0.027 0.78 ± 0.031 0.829 ± 0.028 
 Lose Shift Ratio 
 T=0 hrs T=6 hrs T=12 hrs T=24 hrs T=48 hrs T=72 hrs T=96 hrs 
vehicle 0.563 ± 0.018 0.531 ± 0.051 0.523 ± 0.034 0.544 ± 0.051 0.506 ± 0.039 0.572 ± 0.053 0.544 ± 0.041 
nicotine 0.488 ± 0.046 0.441 ± 0.046 0.52 ± 0.073 0.479 ± 0.088 0.619 ± 0.06 0.523 ± 0.058 0.468 ± 0.052 
Data are means (±s.e.m.) for n=8 rats per treatment group, except for omissions, where data are 
medians (±semi-quartile range). ** p<0.01, * p<0.05 w.r.t. baseline (T=0 hrs).  p<0.01,  p<0.05 w.r.t 
vehicle group. 
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Table 3.  The effect of nicotine and varenicline on probabilistic response reversal (PRL) performance 
across time, during withdrawal from chronic nicotine treatment. 
 Total Pellets (n) 
 T=0 hrs T=6 hrs T=12 hrs T=24 hrs T=30 hrs T=36 hrs 
vehicle 120.3 ± 3.9 103.6 ± 7.7 120.0 ± 3.1      63.8 ± 8.2 **      76.2 ± 9.4 ** 113.9 ± 4.9 
nicotine (0.2 mg/kg) 110.9 ± 4.4 107.4 ± 7.5 118.3 ± 2.3 100.6 ± 8.5     69.6 ± 11.8 $ 113.5 ± 6.1 
varenicline (0.3 mg/kg)  113.3 ± 4.3 99.2 ± 9.9 119.6 ± 2.6 89.7 ± 9.9     67.0 ± 8.2 ** 106.6 ± 5.3 
varenicline (1.0 mg/kg) 
119.0 ± 2.5 
  104.0 ± 3.6 
** 120.1 ± 3.4 96.5 ± 9.8  94.3 ± 11.9 119.9 ± 3.4 
 Errors (n) 
 T=0 hrs T=6 hrs T=12 hrs T=24 hrs T=30 hrs T=36 hrs 
vehicle 67.0 ± 3.4 59.9 ± 5.0 63.5 ± 1.5      40.9 ± 5.8 **    49.3 ± 5.9  63.0 ± 3.7 
nicotine (0.2 mg/kg) 68.1 ± 2.6 61.3 ± 3.0 68.8 ± 3.8 61.0 ± 6.6      31.5 ± 4.2 **    54.8 ± 3.3 * 
varenicline (0.3 mg/kg)  73.3 ± 5.1 66.5 ± 3.4 67.6 ± 2.8      46.1 ± 4.7 **      40.2 ± 3.6 ** 59.3 ± 3.5 
varenicline (1.0 mg/kg) 66.0 ± 2.7 69.8 ± 3.4 61.6 ± 2.2 54.2 ± 4.9 53.0 ± 5.4 63.8 ± 2.1 
 Total Session Time (s) 
 T=0 hrs T=6 hrs T=12 hrs T=24 hrs T=30 hrs T=36 hrs 
vehicle 1923.2 ± 101.6 2288.5 ± 111.5 2137.8 ± 131.7 2400.0 ± 0.0 2390.1 ± 9.8 2178 ± 87.50 
nicotine (0.2 mg/kg) 1757.5 ± 125.4 2195.1 ± 103.2 1758.8 ± 73.99 2190.5 ± 101.5 2400.0 ± 0.0 2257.3 ± 84.80 
varenicline (0.3 mg/kg)  1793.8 ± 91.0 2203.0 ± 97.5 1898.2 ± 94.7 2400.0 ± 0.0 2400.0 ± 0.0 2388.2 ± 11.7 
varenicline (1.0 mg/kg) 1681.6 ± 90.1 2179.5 ± 103.7 1708.3 ± 98.9 2103.0 ± 160.0 2381.2 ± 17.2 2151.6 ± 86.3 
 Win Stay Ratio 
 T=0 hrs T=6 hrs T=12 hrs T=24 hrs T=30 hrs T=36 hrs 
vehicle 0.79 ± 0.03 0.74 ± 0.03 0.80 ± 0.01 0.71 ± 0.04 0.77 ± 0.04 0.83 ± 0.02 
nicotine (0.2 mg/kg) 0.81 ± 0.02 0.78 ± 0.03 0.82 ± 0.03 0.78 ± 0.03 0.78 ± 0.06 0.83 ± 0.04 
varenicline (0.3 mg/kg)  0.78 ± 0.03 0.73 ± 0.06 0.80 ± 0.03 0.83 ± 0.01 0.75 ± 0.05 0.78 ± 0.04 
varenicline (1.0 mg/kg) 0.83 ± 0.02 0.78 ± 0.01 0.83 ± 0.02 0.82 ± 0.01 0.80 ± 0.02 0.83 ± 0.02 
 Lose Shift Ratio 
 T=0 hrs T=6 hrs T=12 hrs T=24 hrs T=30 hrs T=36 hrs 
vehicle 0.52 ± 0.05 0.45 ± 0.05 0.57 ± 0.04 0.58 ± 0.06 0.53 ± 0.06 0.58 ± 0.04 
nicotine (0.2 mg/kg) 0.60 ± 0.03 0.60 ± 0.04 0.68 ± 0.03 0.56 ± 0.05 0.51 ± 0.05 0.62 ± 0.03 
varenicline (0.3 mg/kg)  0.53 ± 0.03 0.47 ± 0.03 0.65 ± 0.03 0.50 ± 0.04 0.56 ± 0.03 0.53 ± 0.07 
varenicline (1.0 mg/kg) 0.53 ± 0.04 0.54 ± 0.04 0.57 ± 0.03 0.59 ± 0.04 0.50 ± 0.06 0.55 ± 0.04 
Data are means (± s.e.m.) for n= 8 rats per treatment group.  *p<0.05, **p<0.01 w.r.t. corresponding 
baseline (t=0 hrs).   p=0.033, adjusted p=0.085.       $ p=0.01, adjusted p=0.05.
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Figure 1.  Performance of a probabilistic response reversal task during withdrawal from chronic 
nicotine treatment or chronic saline.  Across time for each treatment group: Panel A shows the 
number of reversals, Panels B shows response latencies and Panels C shows the total time on task. 
N=8 rats per treatment group.  * p<0.05, **p<0.01 w.r.t. baseline before withdrawal (T=0 hrs). 
 
 
 
 
Figure 2.  The effect of nicotine and varenicline on performance of the probabilistic response 
reversal task during withdrawal from chronic nicotine treatment.  Acute injections of drug (or 
vehicle) were administered at 12 hrs and again at 24 hrs withdrawal.  Panel A shows the number of 
reversals across time for each treatment group. * p<0.05, **p<0.01 w.r.t. corresponding baseline.  
Panels B shows response latencies across time for the vehicle treatment group (left) as well as 
results for each treatment group at 12 hrs and 24hrs withdrawal.  * p<0.05, **p<0.01 w.r.t. 
corresponding vehicle control group.  Panels C shows omissions across time for the vehicle 
treatment group (left) and results for all treatment groups at 24hrs withdrawal. * p<0.05, **p<0.01 
w.r.t. corresponding vehicle control group.  N=8 rats per treatment group.   
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Figure 1 
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Figure 2 
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